Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Levalbuterol toxicity: no reason to be jittery

A.K. Biswas, W.C. Fruedenthal
European Respiratory Journal 2003 21: 1081; DOI: 10.1183/09031936.03.00115802
A.K. Biswas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W.C. Fruedenthal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editor:

Levalbuterol, the R-isomer of racemic albuterol, is a more effective bronchodilator with fewer side-effects than racemic albuterol 1–3. We present a paediatric patient in status asthmaticus who received twelve times the prescribed dose of levalbuterol and manifested only mild systemic side-effects.

This 4-yr-old African-American male was admitted to the Pediatric Intensive Care Unit (Portsmouth, VA, USA) where continuous nebulised levalbuterol was ordered at 0.63 mg·h−1. The nebuliser chamber was erroneously filled with twelve 0.63 mg unit-dose ampoules, delivering 7.56 mg·h−1 of levalbuterol. This dosing regimen was continued for twelve hours before it was discovered.

On the morning rounds, the child was noted to be tachypneic and tachycardic, with a respiratory rate in the mid 40s and cardiac frequency in the range of 150–170 beats·min−1. Oxygen saturation was 97–100% on an inspiratory oxygen fraction of 0.3. The patient was sleeping without any respiratory difficulty. The levalbuterol dose was reduced to 1.25 mg·h−1 and serum electrolytes were obtained. These were completely within normal limits, including potassium of 4.0 mmol·L−1. The patient was weaned off continuous nebuliser treatments over the following 8 h and was transferred to the paediatric ward the next day. The remainder of his hospital course was without incident and he was discharged in good condition.

Racemic albuterol contains both R-albuterol (levalbuterol), which has bronchodilatory activity, and S-levalbuterol, initially thought to be inert. Studies have demonstrated that the S-levalbuterol not only increases intracellular-free calcium, which is an agonist in airway smooth muscle contraction, butalso has significant proinflammatory effects, including increasing the production of histamine and interleukin-4 in mast cells 3–5. These results support the concept that the S-levalbuterol may have significant detrimental effects on pulmonary function in an acute asthma exacerbation. Reported side-effects of levalbuterol in the studies of both Nelson et al. 1 and Gawchik et al. 2 included increased heart frequency, tremor and hypokalaemia that were dose related but similar between the two study groups.

In the intensive care unit (ICU) setting, dosing of racemic albuterol as high as 20 mg·h−1 in children with status asthmaticus is not uncommon. However, therapeutic dosing oflevalbuterol in asthmatics at >1.25 mg has not been previously reported. Tremor, heart rate and hypokalaemia were dose related following inhalation of increasing doses of levalbuterol (0.2–3.2 mg) in normal volunteers. However, our patient received a dose twice that given to these volunteers and experienced only minimal side-effects.

We also believe that this may be the first report on the use of continuous levalbuterol nebulisation in an inpatient setting for children. The National Asthma Education Program, Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma-No. 91-3042, recommended using racemic albuterol up to every 1–2 h for moderately ill children and continuous nebulisation for severely ill children in the ICU setting. Our dosing guideline was based upon these recommendations and previous studies, suggesting levalbuterol at 0.63 mg as the starting dose and escalating to 1.25 mg if necessary 1, 2.

This case illustrates that the safety profile for levalbuterol may be more generous in paediatric patients than previously reported. Furthermore, continuous nebulised levalbuterol canbe easily and safely delivered in the intensive care unit setting, both to intubated and nonintubated patients. However, we suggest further studies with other levalbuterol dosing regimens should be conducted before there is widespread use of doses >1.25 mg.

    • © ERS Journals Ltd

    References

    1. ↵
      Nelson HS, Bensch G, Pleskow WW, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998;102:943–952.
      OpenUrlCrossRefPubMedWeb of Science
    2. ↵
      Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999;103:615–621.
      OpenUrlCrossRefPubMedWeb of Science
    3. ↵
      Mitra S, Ugur M, Ugur O, Goodman HM, McCullough JR, Yamaguchi H. (S)-albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharm 1998;53:347–354.
      OpenUrlAbstract/FREE Full Text
    4. Volcheck GW, Gleich GJ, Kita H. Pro- and anti-inflammatory effects of beta adrenergic agonists on eosinophil response to IL-5. J Allergy Clin Immunol 1998;101:S35.
      OpenUrl
    5. ↵
      Cho SH, Hartleroad JY, Oh CK. (S)-albuterol increases the production of histamine and IL-4 in mast cells. Int Arch Allergy Immunol 2001;124:478–484.
      OpenUrlCrossRefPubMedWeb of Science
    PreviousNext
    Back to top
    View this article with LENS
    Vol 21 Issue 6 Table of Contents
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Levalbuterol toxicity: no reason to be jittery
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Levalbuterol toxicity: no reason to be jittery
    A.K. Biswas, W.C. Fruedenthal
    European Respiratory Journal Jun 2003, 21 (6) 1081; DOI: 10.1183/09031936.03.00115802

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Levalbuterol toxicity: no reason to be jittery
    A.K. Biswas, W.C. Fruedenthal
    European Respiratory Journal Jun 2003, 21 (6) 1081; DOI: 10.1183/09031936.03.00115802
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Refined risk stratification in PAH and timing of lung transplantation
    • COVID-19 drug research and the cohort multiple randomised controlled trial design
    • COVID-19 drug research and the cohort multiple randomised controlled trial design
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2022 by the European Respiratory Society